EP1507553A2 - Proteines specifiques du pancreas - Google Patents

Proteines specifiques du pancreas

Info

Publication number
EP1507553A2
EP1507553A2 EP03735505A EP03735505A EP1507553A2 EP 1507553 A2 EP1507553 A2 EP 1507553A2 EP 03735505 A EP03735505 A EP 03735505A EP 03735505 A EP03735505 A EP 03735505A EP 1507553 A2 EP1507553 A2 EP 1507553A2
Authority
EP
European Patent Office
Prior art keywords
nucleic acid
polypeptide
proteins
acid molecule
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03735505A
Other languages
German (de)
English (en)
Inventor
Cord Dohrmann
Matthias Austen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec International GmbH
Original Assignee
Develogen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen AG filed Critical Develogen AG
Priority to EP03735505A priority Critical patent/EP1507553A2/fr
Priority to EP10180071A priority patent/EP2275118A3/fr
Priority to EP10180055A priority patent/EP2269628A3/fr
Publication of EP1507553A2 publication Critical patent/EP1507553A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

L'invention concerne des polynucléotides identifiant et codant DP119, DP444, DP810, DP685, WE474, DP160, RA977, ou RA770, ainsi que des nouvelles fonctions pour ces protéines de l'invention. Cette invention concerne également des compositions utiles contre des troubles associés à l'expression de protéines de l'invention, notamment dans le traitement, le soulagement et/ou la prévention de dysfonctionnement du pancréas (par exemple le diabète, l'hyperglycémie, et l'intolérance au glucose), de troubles associés, ainsi que d'autres maladies et troubles.
EP03735505A 2002-05-29 2003-05-30 Proteines specifiques du pancreas Withdrawn EP1507553A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP03735505A EP1507553A2 (fr) 2002-05-29 2003-05-30 Proteines specifiques du pancreas
EP10180071A EP2275118A3 (fr) 2002-05-29 2003-05-30 Proteines specifiques du pancreas
EP10180055A EP2269628A3 (fr) 2002-05-29 2003-05-30 Proteines specifiques du pancreas

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP02011963 2002-05-29
EP02011963 2002-05-29
EP02020829 2002-09-17
EP02020829 2002-09-17
EP03735505A EP1507553A2 (fr) 2002-05-29 2003-05-30 Proteines specifiques du pancreas
PCT/EP2003/005700 WO2003099318A2 (fr) 2002-05-29 2003-05-30 Proteines specifiques du pancreas

Publications (1)

Publication Number Publication Date
EP1507553A2 true EP1507553A2 (fr) 2005-02-23

Family

ID=29585693

Family Applications (3)

Application Number Title Priority Date Filing Date
EP03735505A Withdrawn EP1507553A2 (fr) 2002-05-29 2003-05-30 Proteines specifiques du pancreas
EP10180055A Withdrawn EP2269628A3 (fr) 2002-05-29 2003-05-30 Proteines specifiques du pancreas
EP10180071A Withdrawn EP2275118A3 (fr) 2002-05-29 2003-05-30 Proteines specifiques du pancreas

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP10180055A Withdrawn EP2269628A3 (fr) 2002-05-29 2003-05-30 Proteines specifiques du pancreas
EP10180071A Withdrawn EP2275118A3 (fr) 2002-05-29 2003-05-30 Proteines specifiques du pancreas

Country Status (4)

Country Link
EP (3) EP1507553A2 (fr)
JP (3) JP2005527614A (fr)
AU (1) AU2003238178A1 (fr)
WO (1) WO2003099318A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1694354T3 (pl) 2003-11-27 2009-12-31 Develogen Ag Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
US20070110728A1 (en) * 2003-11-28 2007-05-17 Develogen Aktiengesellschaft Method for preventing and treating diabetes using dg119
EP1872790A1 (fr) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft Nouvelle formulation pour augmenter la biodisponibilité de neurturine
WO2008015023A2 (fr) * 2006-08-04 2008-02-07 Develogen Aktiengesellschaft Utilisation de produits de photomédine pour la prévention et/ou le traitement de dysfonctionnements neuronaux
CA2742839A1 (fr) 2007-11-05 2009-05-14 Develogen Aktiengesellschaft Nouveaux conjugues de neurturine pour une utilisation pharmaceutique
JP5794511B2 (ja) * 2010-08-31 2015-10-14 国立大学法人 東京大学 オートタキシン測定による膵疾患の検査方法および検査薬
EP3135766B1 (fr) * 2014-04-24 2020-12-02 Ribomic Inc. Aptamère utilisé pour se lier à l'autotaxine et pour inhiber l'activité biologique de l'autotaxine, et son utilisation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5605662A (en) 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US5731167A (en) 1992-01-17 1998-03-24 The United States Of America As Represented By The Department Of Health And Human Services Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6222022B1 (en) 1996-03-14 2001-04-24 Washington University Persephin and related growth factors
US6043221A (en) 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
WO1999038972A2 (fr) 1998-01-28 1999-08-05 Chiron Corporation Genes humains et produits ii d'expression genique
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
WO2000018922A2 (fr) * 1998-10-01 2000-04-06 Incyte Genomics, Inc. Proteines humaines associees a des glucides
IL146237A0 (en) * 1999-05-07 2002-07-25 Zymogenetics Inc Autotaxin variants and uses to treat diseases of metabolism
WO2001053312A1 (fr) 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
WO2001059064A2 (fr) 2000-01-31 2001-08-16 Human Genome Sciences, Inc. Acides nucleiques, proteines et anticorps
AU2001233114A1 (en) * 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
JP2004509612A (ja) 2000-06-05 2004-04-02 アバロン　ファーマシューティカルズ ガン遺伝子決定および特徴的な遺伝子群を用いた治療用スクリーニング
US20040110668A1 (en) 2000-10-02 2004-06-10 Burgess Christopher C. Nucleic acid sequences differentially expressed in cancer tissue

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLAUSS I M ET AL: "In situ hybridization studies suggest a role for the basic region-leucine zipper protein hXBP-1 in exocrine gland and skeletal development during mouse embryogenesis", DEVELOPMENTAL DYNAMICS 1993 US, vol. 197, no. 2, 1993, pages 146 - 156, ISSN: 1058-8388 *

Also Published As

Publication number Publication date
WO2003099318A3 (fr) 2004-05-06
JP5754698B2 (ja) 2015-07-29
EP2275118A3 (fr) 2011-10-19
EP2275118A2 (fr) 2011-01-19
AU2003238178A1 (en) 2003-12-12
JP2010229133A (ja) 2010-10-14
WO2003099318A2 (fr) 2003-12-04
EP2269628A3 (fr) 2011-04-20
JP2005527614A (ja) 2005-09-15
JP2013227318A (ja) 2013-11-07
EP2269628A2 (fr) 2011-01-05

Similar Documents

Publication Publication Date Title
US6777388B1 (en) Leptin-related peptides
JP2004526444A (ja) Ｓｔｅａｐ関連タンパク質
JP2002502589A (ja) ４５個のヒト分泌タンパク質
JP5754698B2 (ja) 膵臓特異性タンパク質
JP2002521055A (ja) ９８個のヒト分泌タンパク質
JP2002525115A (ja) 発作、高血圧、糖尿病および肥満を予報および治療する、遺伝子およびタンパク質
JP2002533058A (ja) ９７個のヒト分泌タンパク質
JP2001515349A (ja) Ｔｍ４ｓｆヒト腫瘍関連抗原
JP2002501738A (ja) ６７個のヒト分泌タンパク質
JP2002506627A (ja) ９５個のヒト分泌タンパク質
US9049849B2 (en) Screening methods for compounds useful for treating pancreatic dysfunction
JP2002514925A (ja) １９個のヒト分泌タンパク質
JP2001517943A (ja) ヒト膵炎関連タンパク質、ｐａｐ−２
JP2004537971A (ja) 大腸癌マーカー
US7211563B2 (en) Protein disulfide isomerase and ABC transporter homologous proteins involved in the regulation of energy homeostasis
JP2004516813A (ja) 関連腫瘍マーカー
JP2002504361A (ja) ３６個のヒト分泌タンパク質
US20040242515A1 (en) Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy home-ostasis
JP2005507398A (ja) エネルギー恒常性の調節に関与するＢｅｓｔｒｏｐｈｉｎおよびＢｅｓｔｒｏｐｈｉｎ相同性タンパク質
WO2003062410A2 (fr) Proteine torero
JP2002501747A (ja) ヒト・成長因子ホモログ
JP2006525031A (ja) Ａｃｈｅｒｏｎ発現の制御方法
US20030175787A1 (en) Vesicle membrane proteins
US9353417B1 (en) Method of diagnosing large granular lymphocyte leukemia using alternative splice variants of serine proteases
US20030044812A1 (en) Cell differentiation cDNAs induced by retinoic acid

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041119

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DEVELOGEN AKTIENGESELLSCHAFT

17Q First examination report despatched

Effective date: 20051222

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EVOTEC INTERNATIONAL GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161112